亲和关系通过目标介导的药物处置影响抗GD2抗体的功能强度
Sascha Troschke-Meurer1, Maxi Zumpe1, Peter Moritz Ahrenberg1
1Department of Pediatric Oncology and Hematology, University Medicine Greifswald, 17475 Greifswald, Germany.
在神经母细胞瘤模型中,dinutuximab beta (DB) 与naxitamab (NAXI) 相比,表现出优异的抗体依赖细胞细胞毒性 (ADCC). 这种增强的功效与naxitamab有关.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 高风险神经母细胞瘤的治疗使用抗GD2抗体:丁西马布β (DB) 和纳西塔马布 (NAXI).
- 了解它们的比较疗效和目标介导药物处置 (TMDD) 对于优化治疗至关重要.
研究的目的:
- 在神经母细胞瘤模型中评估DB与NAXI的功能功效.
- 研究这些抗体的目标介导药物排放 (TMDD) 的机制.
主要方法:
- 使用了具有不同GD2表达的神经母细胞瘤球体.
- 评估了抗体依赖性细胞毒性 (ADCC) 和补体依赖性细胞毒性 (CDC).
- 分析了结合活性,抗体内化和可溶性GD2 (sGD2) 对ADCC的影响.
主要成果:
- 无论是DB还是NAXI都诱导了对GD2-阳性球体的度依赖ADCC.
- DB的ADCC强度明显高于NAXI. DB的ADCC强度明显高于NAXI.
- NAXI显示出对细胞的结合减少更大,并增加了瘤和免疫细胞的内部化,sGD2更严重地损害了NAXI介导的ADCC.
结论:
- 在临床度下,dinutuximab beta (DB) 与naxitamab (NAXI) 相比显示出更高的ADCC强度.
- 纳克西的效率降低归因于更明显的向中介药物排放 (TMDD) 影响,包括增加内化和对可溶性GD2.2的敏感性.
更多相关视频
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
相关概念视频
Affinity and Avidity
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
